International study shows wide differences in 5-year survival rates across the globe
the ONA take:
According to a new study published in the journal The Lancet, there are very large differences in 5-year survival among patients with cancer between 67 countries.
For the CONCORD-2 study, researchers used patient data from 279 cancer registries and identified 25.7 million patients with cancer diagnosed with one of the 10 most common cancers, as well as 75,000 children diagnosed with acute lymphoblastic leukemia (ALL) between 1995 and 2009.
Results showed that pediatric patients with ALL had various different 5-year survival rates depending upon what country they reside in. Patients from Indonesia, Jordan, Lesotho, Mongolia, and Tunisia had a 5-year survival rate between 16% and 50%, while patients in Austria, Belgium, Canada, Germany, and Norway had a 5-year survival rate over 90%.
Among the 10 most common cancers, Israel and Ecuador had the highest survival for colon cancer (≥68%); Cyprus, Iceland, and Japan had the highest for rectal cancer (≥70%); and Australia, Brazil, Canada, Cyprus, Israel, Japan, the U.S. and many European countries had the highest survival for breast cancer (≥85%). Mongolia had the lowest survival for breast, colon, and rectal cancers. In Europe, European Russia had the lowest survival for those three cancers.
There are very large differences in 5-year survival among patients with cancer between 67 countries.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|